What is the 13F Pro Quality Score for NXGL?

13F Pro ranks NEXGEL, INC. (NXGL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NXGL's current score at https://13fpro.ai/research/NXGL (free sign-up required for the full ranking).

Which hedge funds own the most NXGL stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NXGL include GEODE CAPITAL MANAGEMENT,, MORGAN STANLEY, ARMISTICE CAPITAL,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NXGL as soon as new 13F filings post.

Where does 13F Pro source NXGL data?

All NEXGEL, INC. fundamentals and ownership data come directly from SEC EDGAR. NEXGEL, INC. files with the SEC under CIK 1468929. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NXGL in?

NEXGEL, INC. (NXGL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NXGL research updated on 13F Pro?

NXGL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NEXGEL, INC.(NXGL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1468929 NXGL stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $11.4M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NXGL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NEXGEL, INC. (NXGL), a Healthcare sector company. NXGL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $11.4m in revenue. Based on the latest XBRL financial filings (Q1 2026), NEXGEL, INC. reports quarterly revenue of $2.6M, net income of $-927.0K, an operating margin of -36.1%. Top institutional holders of NXGL by reported 13-F value include GEODE CAPITAL MANAGEMENT,, MORGAN STANLEY, ARMISTICE CAPITAL,, based on the most recent SEC filings. NXGL trades on the Nasdaq exchange and files with the SEC under CIK 1468929. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NXGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEXGEL, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$2.6M

Net Income

Q1 2026

$-927.0K

Free Cash Flow

Q1 2026

$-513.0K

Operating Margin

Q1 2026

-36.1%

D/E Ratio

Q1 2026

0.14

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+31.5% YoY

$11.4MFY 2025

FY22 $2.0MFY23 $4.1MFY24 $8.7MFY25 $11.4M

Net Income

+8.6% YoY

$-3.0MFY 2025

FY22 $-4.7MFY23 $-3.2MFY24 $-3.3MFY25 $-3.0M

Operating Income

+5.7% YoY

$-3.4MFY 2025

FY22 $-3.3MFY23 $-3.5MFY24 $-3.6MFY25 $-3.4M

EPS (Diluted)

+24.0% YoY

$-0.38FY 2025

FY22 $-0.85FY23 $-0.56FY24 $-0.50FY25 $-0.38

Total Assets

-4.8% YoY

$10.5MFY 2025

FY22 $10.4MFY23 $10.0MFY24 $11.0MFY25 $10.5M

Total Debt

-14.2% YoY

$588.0KFY 2025

FY22 $283.0KFY23 $838.0KFY24 $685.0KFY25 $588.0K

Op. Cash Flow

+66.1% YoY

$-1.3MFY 2025

FY22 $-3.0MFY23 $-3.2MFY24 $-3.9MFY25 $-1.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$11.4M +31.5%	$8.7M +112.5%	$4.1M +99.7%	$2.0M +32.0%	$1.6M +130.1%	$674.0K
Net Income	$-3.0M +8.6%	$-3.3M -3.9%	$-3.2M +33.5%	$-4.7M -10.1%	$-4.3M -90.4%	$-2.3M
Operating Income	$-3.4M +5.7%	$-3.6M -2.2%	$-3.5M -3.9%	$-3.3M -30.3%	$-2.6M -13.7%	$-2.3M
EPS (Diluted)	$-0.38 +24.0%	$-0.50 +10.7%	$-0.56 +34.1%	$-0.85 +41.4%	$-1.45 -38.1%	$-1.05
Total Assets	$10.5M -4.8%	$11.0M +10.3%	$10.0M -3.9%	$10.4M -39.0%	$17.0M +652.5%	$2.3M
Total Debt	$588.0K -14.2%	$685.0K -18.3%	$838.0K +196.1%	$283.0K	—	—
Operating Cash Flow	$-1.3M +66.1%	$-3.9M -19.5%	$-3.2M -8.2%	$-3.0M -8.7%	$-2.8M -52.9%	$-1.8M

AI Insight: NXGL Financial Trends

NXGL remains unprofitable with stalled revenue growth at $3M for eight consecutive quarters and persistent operating losses.

• Revenue plateaued at $3M/quarter since Q3 2024, with no growth trajectory evident through Q1 2026.

• Operating cash flow deteriorated to -$1M in Q1 2026 after brief improvement to $0M in Q4 2025.

• Equity declined from $6M in Q4 2024 to $4M in Q1 2026, eroded by sustained net losses.

⚠ Company burning cash with negative operating cash flow in 5 of 8 quarters; runway sustainability unclear.

⚠ Net losses of $1M/quarter on $3M revenue imply gross margin pressure or high fixed costs requiring intervention.

AI Insight: NXGL Ratio Trends

NXGL remains deeply unprofitable with deteriorating profitability metrics in Q1 2026, reversing modest gains from mid-2025.

• Operating margin worsened to -36.1% in Q1 2026 from -24.7% in Q3 2025, erasing sequential improvement.

• Net profit margin declined to -35.0% in Q1 2026 from -22.2% in Q3 2025, indicating cost control deterioration.

• ROIC collapsed to -84.1% in Q1 2026 versus -50.0% in Q3 2025, the steepest reversal in the dataset.

⚠ ROE sank to -92.8% in Q1 2026, worst in 18 months, signaling shareholder value destruction accelerating.

⚠ Debt-to-equity ratio stable near 0.13–0.14 but leverage offers no cushion against persistent operating losses.

Get alerted when NXGL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NEXGEL, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NXGL

GEODE CAPITAL MANAGEMENT, LLC
$81.4K128,536 sh
MORGAN STANLEY
$34.8K54,980 sh
ARMISTICE CAPITAL, LLC
$32.9K550,000 sh
RENAISSANCE TECHNOLOGIES LLC
$32.3K50,960 sh
JANE STREET GROUP, LLC
$26.7K42,138 sh
SIMON QUICK ADVISORS, LLC
$22.6K35,715 sh
FLAX POND CAPITAL, LLC
$12.7K20,000 sh
GTS SECURITIES LLC
$12.2K19,347 sh
XTX Topco Ltd
$11.1K17,585 sh
STATE STREET CORP
$10.9K17,259 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$81.4K	128,536
MORGAN STANLEY	$34.8K	54,980
ARMISTICE CAPITAL, LLC	$32.9K	550,000
RENAISSANCE TECHNOLOGIES LLC	$32.3K	50,960
JANE STREET GROUP, LLC	$26.7K	42,138
SIMON QUICK ADVISORS, LLC	$22.6K	35,715
FLAX POND CAPITAL, LLC	$12.7K	20,000
GTS SECURITIES LLC	$12.2K	19,347
XTX Topco Ltd	$11.1K	17,585
STATE STREET CORP	$10.9K	17,259

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NXGL on your watchlist

Track score changes the day NEXGEL, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NXGL a good stock to buy?

13F Pro's AI-powered analysis of NEXGEL, INC. (NXGL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NXGL are available on the NXGL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NXGL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NXGL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEXGEL, INC.'s investment landscape.